NCT06229769 Natural History Study for Patients With Angelman Syndrome
| NCT ID | NCT06229769 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Liege |
| Condition | Angelman Syndrome |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2021-10-10 |
| Primary Completion | 2028-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2021-10-10 with a primary completion date of 2028-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study is a 9-year natural history study for patients with Angelman syndrome in Belgium (a genetic neurodevelopmental disorder, affecting 500,000 individuals in the world). It includes a 3-year recruitment phase, a 5 year follow-up and a year to analyze the collected data. The investigators plan to include 30 patients with a semi-annual follow-up for 4 years. The investigators will collect relevant retrospective and prospective data using age-standardized scales and questionnaires for functional motor assessments and global developmental assessment.
Eligibility Criteria
Inclusion Criteria: * Genetically confirmed diagnosis of AS * 0-99 years * Male or Female * Participant's carer is willing to give IC/sign a "record of consultation" for participation in the study Exclusion Criteria: * comorbidity that could potentially affect the results of the study coexists. This
Contact & Investigator
Laura Vanden Brande
PRINCIPAL INVESTIGATOR
CHR Citadelle
Frequently Asked Questions
Who can join the NCT06229769 clinical trial?
This trial is open to participants of all sexes, studying Angelman Syndrome. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06229769 currently recruiting?
Yes, NCT06229769 is actively recruiting participants. Contact the research team at Noor.Benmhammed@citadelle.be for enrollment information.
Where is the NCT06229769 trial being conducted?
This trial is being conducted at Liège, Belgium.
Who is sponsoring the NCT06229769 clinical trial?
NCT06229769 is sponsored by Centre Hospitalier Universitaire de Liege. The principal investigator is Laura Vanden Brande at CHR Citadelle. The trial plans to enroll 30 participants.